Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewHistoric kainate/quisqualate selective antagonist; may be able to distinguish between AMPA and kainate receptors. Anticonvulsant.
M. Wt | 240.23 |
Storage | Store at RT |
CAS Number | 90237-02-8 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Croucher et al (1984) γ-D-Glutamylaminomethylsulphonic acid (GAMS), a kainate and quisqualate antagonist, prevents sound-induced seizures in DBA/2 mice. Brain Res. 322 111 PMID: 6097331
Wilding and Huettner (1996) Antagonist pharmacology of kainate- and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol.Pharmacol. 49 540 PMID: 8643094
Zhou et al (1993) γ-D-Glutamylaminomethyl sulfonic acid (GAMS) distinguishes kainic acid- from AMPA-induced response in Xenopus oocytes expressing chick brain glutamate receptors. Neuropharmacology 32 767 PMID: 7692340
Keywords: GAMS, GAMS supplier, Non-selective, Ionotropic, Glutamate, 0150, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for GAMS.
There are currently no reviews for this product. Be the first to review GAMS and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.